In a major breakthrough, scientists led by Elena Deryugina at The Scripps Research Institute (TSRI) identified a specific protein, Latent TGFβ Binding Protein 3—LTBP3 for short—that kicks off a cellular chain reaction resulting in early-development tumors growing new blood vessels. These vessels then act like highways to spread cancer cells throughout the body, seeding metastatic tumors very early on. The crux discovery has to do with the “T” in LTBP3, TGFβ, a protein that has long caught the attention of cancer researchers as a target for chemotherapy drugs. Having multiple roles in healthy people and in disease, TGFβ can be…
Author: Global Cancer Consortium
Greg Simon is the president of the Biden Cancer Initiative, formerly called The Cancer Moonshot, the goal was to try to make ten years of progress in five years. It was kicked off by President Obama and led by Joe Biden. Greg has been involved since the outset. Brett Johnson: So, Greg, what is the mission of the Biden Cancer Initiative? Greg Simon: Our mission is very similar to what we did in The Cancer Moonshot in the White House, which is to double our rate of progress in the prevention, detection, diagnosis, treatment and survivorship of cancer. We are…
The Cancer Investor Conference October 30th & 31st to Unveil Global Cancer Database for Investors NEW YORK – Altru Institute, organizer of the Global Cancer Consortium, has announced that a global database of innovative cancer companies will premiere at the Cancer Investor Conference in New York, October 30 – 31. The event will showcase promising opportunities in emerging private and public companies focused on cancer. Progress is best advanced if there is a high amount of collaboration among the organizations working towards cures and treatments said Brett Johnson, co-founder of Altru Institute. “Our role is to identify the promising…
Two days of exceptional programming and networking anchored by 28 oncology companies. Attending investors heard insights from Jack Hidary Google Artificial Intelligence strategist provided insight on the future role of AI treating Cancer. Dr. Sujuan Ba, President of National Foundation for Cancer Research gave outlook on Cancer research. Prolific biotech investor and Celgene founder Isaac Blech described keys to success in early biotech Investing. Aisling Capital, Founder Dennis Purcell described the development of new financial instruments, specifically a futures market for managing risk in the healthcare sector. Former J&J executive Lili Gil Valletta, presented on how big data and AI tools can uncover weaknesses in the delivery…
Cervical Cancer Cervical cancer continues to affect women of all ages worldwide. The disease often presents no symptoms in its early stages, which is why it is often referred to as a “silent killer.” Most cervical cancers are caused by the human papillomavirus (HPV), a common virus that can be passed from one person to another through sexual activity. With the advent of the HPV vaccine and regular Pap screening tests, most cervical cancers can now be prevented. In 2017, it is estimated that nearly 13,000 women will be diagnosed with invasive cervical cancer in the U.S. and more than…
Breast Cancer Breast cancer is the most common cancer in women worldwide, claiming the lives of hundreds of thousands of women each year. Although it’s rare, men can also be diagnosed with breast cancer. With breast cancer continuing to impact so many people, it’s important to understand the disease and what strides researchers are making. More than 3.1 million breast cancer survivors live in the U.S. today. The lifetime risk of getting breast cancer in the U.S. is about 1 in 8 for women and 1 in 1,000 for men. Research shows only 5-10% of breast cancers are hereditary. Dense…
ALISO VIEJO, Calif. & SAVANNAH, Ga.–(BUSINESS WIRE)–Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists, and the pharmaceutical industry, and Health Discovery Corporation (HDC) (OTCBB: HDVY) a leader in support vector machine (SVM) based molecular diagnostic and prognostic test development, today announced that the companies have completed the three-phased, double-blind clinical validation studies for their new gene-based molecular diagnostic test for prostate cancer. Results from Phase I, Phase II and Phase III double-blinded clinical validation studies on prostate tissues obtained from multiple sites, including those tested in collaboration with MD Anderson Cancer Center…
Now in its 19th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. With a mission to support industry-wide success, the conference offers a broad and unbiased view of investment opportunities. BIO CEO sets itself apart by providing a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. This year’s conference was no exception, as it featured issue-oriented and educational sessions focused on trending therapeutic areas and key business issues, company presentations, one-on-one meetings,…